Core Viewpoint - The stock of Basilea Pharmaceutica (02616) has increased over 6%, with a cumulative rise of over 25% in the month, reflecting positive market sentiment following recent regulatory approvals [1] Group 1: Regulatory Approvals - Basilea Pharmaceutica announced that its PD-L1 antibody, Sugli monoclonal antibody, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a new indication in Phase III non-small cell lung cancer (NSCLC) [1] - This approval follows the European Commission (EC) license obtained in July 2024, marking a significant breakthrough in the European core market [1] Group 2: Clinical Trials - Basilea's core asset, CS2009, has received FDA approval for its Investigational New Drug (IND) application for a Phase II clinical trial targeting advanced solid tumors [1] - CS2009 is a tri-specific antibody targeting PD-1/VEGF/CTLA-4, indicating important progress in the global development of this innovative immunotherapy [1]
港股异动 | 基石药业-B(02616)再涨超6% 月内涨超25% 舒格利单抗III期NSCLC获英国正式批准